StockNews.com Downgrades Humana (NYSE:HUM) to Hold

Humana (NYSE:HUM) was downgraded by research analysts at StockNews.com from a “buy” rating to a “hold” rating in a research report issued on Wednesday.

Other analysts also recently issued research reports about the company. JPMorgan Chase & Co. dropped their price target on Humana from $257.00 to $256.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 18th. Cantor Fitzgerald reiterated a “neutral” rating and set a $290.00 price target on shares of Humana in a research note on Wednesday, February 12th. Royal Bank of Canada reiterated an “outperform” rating and set a $283.00 price target on shares of Humana in a research note on Wednesday, February 12th. Truist Financial boosted their price target on Humana from $260.00 to $290.00 and gave the company a “hold” rating in a research note on Monday, January 6th. Finally, Piper Sandler boosted their price target on Humana from $270.00 to $288.00 and gave the company a “neutral” rating in a research note on Wednesday, January 15th. Twenty research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $285.68.

Humana Trading Up 0.8 %

Shares of NYSE:HUM opened at $263.74 on Wednesday. The business’s 50-day moving average is $271.40 and its 200 day moving average is $285.08. Humana has a 1 year low of $213.31 and a 1 year high of $406.46. The firm has a market capitalization of $31.82 billion, a P/E ratio of 26.51, a P/E/G ratio of 2.05 and a beta of 0.57. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.76 and a quick ratio of 1.76.

Humana (NYSE:HUM) last announced its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. On average, research analysts predict that Humana will post 16.47 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Timothy S. Huval sold 3,703 shares of the company’s stock in a transaction dated Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total value of $948,930.78. Following the completion of the transaction, the insider now owns 8,181 shares of the company’s stock, valued at approximately $2,096,463.06. This represents a 31.16 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.32% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Humana

Hedge funds have recently made changes to their positions in the company. Creative Financial Designs Inc. ADV raised its holdings in shares of Humana by 244.0% during the third quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider’s stock valued at $27,000 after acquiring an additional 61 shares during the last quarter. FPC Investment Advisory Inc. acquired a new position in shares of Humana during the fourth quarter valued at approximately $27,000. Centricity Wealth Management LLC acquired a new position in shares of Humana during the fourth quarter valued at approximately $30,000. Ashton Thomas Securities LLC acquired a new position in shares of Humana during the third quarter valued at approximately $31,000. Finally, LFA Lugano Financial Advisors SA raised its holdings in shares of Humana by 56.3% during the fourth quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider’s stock valued at $32,000 after acquiring an additional 45 shares during the last quarter. Institutional investors and hedge funds own 92.38% of the company’s stock.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.